Recent
Major U.S. insurers are cutting coverage for GLP-1 drugs used in obesity care citing steep costs, affecting millions of Americans and intensifying debate over treatment access.
October 13, 2025
Source:
CNN
GLP-1 Coverage Cuts Hit Millions
Who Is Affected?
GLP-1 drugs—including Wegovy, Ozempic, Saxenda and Zepbound—have seen widespread insurance coverage reductions for obesity care across the U.S. in 2025. Source: KFF.
Kaiser Permanente: Ended base coverage in California, with exceptions only via special riders or BMI over 40. LA Times
NC Medicaid: Dropped GLP-1 coverage for obesity from Oct 1, 2025. WRAL
Colorado: State employee health plan coverage removed; some grandfathered with higher copays.
Medicare and Medicaid: No coverage for weight-loss GLP-1s in 2026 due to projected $35 billion/year costs. STAT News
Main Drivers
Surcharges and high medication prices—often $1,000 or more monthly—are cited by insurers as the key reason. Employers face up to a 14% hike in health insurance premiums if these drugs are widely covered, according to analysis by Health Affairs.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Getty Images
Access Barriers and Patient Impact
Coverage Gaps
As of 2025, an estimated 97 million Americans will lack commercial insurance coverage for new GLP-1 obesity drugs. Another 19 million will have no GLP-1 obesity prescriptions covered at all, per GoodRx.
Restrictions: Many plans that retain some coverage require prior authorizations, high copays, or proof of failed weight management attempts.
Diabetes Use: GLP-1 drugs remain covered for FDA-approved diabetes and cardiovascular risk reduction, but weight loss coverage is only allowed under strict conditions.
Cost Burden
Out-of-pocket costs soar for those losing insurance. Full price is often over $1,000 per month. "Compounded versions are no longer an option due to recent regulatory changes," experts note (FDA).
Read More
Source:
Shutterstock
Advocacy and the Search for Solutions
Push for Broader Access
Obesity advocates are pressuring lawmakers and agencies, labeling the disease a chronic condition requiring medical treatment—"not just lifestyle advice", says the Obesity Action Coalition.
Groups are seeking a legislative or policy champion to expand access at the federal and state levels.
Employers weigh supplemental coverage options but cite unsustainable premium hikes.
Alternatives and Coverage
Insurers promote behavioral or lifestyle programs as alternatives, but reviews show such programs rarely achieve similar weight loss to GLP-1 drugs (JAMA).
Summary Table
Insurer/Program | 2025 Coverage for Obesity | Details |
|---|---|---|
Kaiser Permanente (CA) | Removed | BMI ≥ 40 or special rider only |
NC Medicaid | Discontinued Oct 1 | No new obesity prescriptions |
Colorado Employees | Discontinued July 1 | Grandfathered, higher copays |
Medicare/Medicaid | Not covered 2026 | Cost cited |
What are the main reasons insurers are dropping GLP-1 coverage?
The primary reasons are rapidly rising medication costs and the impact on insurance premiums, which could increase by double digits for employers.
How are advocates planning to address the lack of GLP-1 coverage?
Are there any alternative treatments for obesity that are covered by insurance?
How does the cost of GLP-1 medications compare to other obesity treatments?
What impact does the lack of GLP-1 coverage have on patients with obesity?
Share this news:
